Robert A. Figlin, MD

Robert A. Figlin, MD, discusses novel combinations in the treatment of patients with kidney cancer.

Robert A. Figlin, MD, discusses the evolving treatment landscape of renal cell carcinoma (RCC).

Robert A. Figlin, MD, Steven Spielberg Family Chair in Hematology Oncology, director, Division of Hematology/Oncology, deputy director, Integrated Oncology Service Line, and professor of Biomedical Sciences, Medicine, at Cedars-Sinai Medical Center, discusses the toxicity profiles of combinations of immune checkpoint inhibitors and VEGF TKIs in renal cell carcinoma (RCC), as well as research being done to validate potential biomarkers in the space.

Robert A. Figlin, MD, director, Division of Hematology/Oncology, Steven Spielberg Professor of Biomedical Sciences and Medicine, Cedars-Sinai Medical Center, discusses the promise of immunotherapy plus TKI combinations in the treatment of patients with renal cell carcinoma.

Robert A. Figlin, MD, director, Division of Hematology/Oncology, Steven Spielberg Professor of Biomedical Sciences and Medicine, Cedars-Sinai Medical Center, discusses next steps for research in the treatment of patients with metastatic renal cell carcinoma.

Robert A. Figlin, MD, director, Division of Hematology/Oncology, Steven Spielberg Professor of Biomedical Sciences and Medicine, Cedars-Sinai Medical Center, discusses the future of treatment for patients with renal cell carcinoma.

Robert A. Figlin, MD, director, Division of Hematology/Oncology, Steven Spielberg Professor of Biomedical Sciences and Medicine, Cedars-Sinai Medical Center, discusses considerations when combining TKIs and immunotherapy agents in the management of advanced renal cell carcinoma.

Robert A. Figlin, MD, director, Division of Hematology/Oncology, professor of biomedical sciences and medicine, Cedars-Sinai Medical Center, discusses the future of kidney cancer treatment.

Robert A. Figlin, MD, director, Division of Hematology/Oncology, professor of biomedical sciences and medicine, Cedars-Sinai Medical Center, discusses the tolerability and toxicity of immune-oncology agents in kidney cancer.

Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology and associate director of academic program development in the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, discusses the major novel agents at the forefront of the treatment landscape of renal cell carcinoma.

Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology and associate director of academic program development in the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, discusses tyrosine kinase inhibitors that he uses to treat patients with renal cell carcinoma.